The AI drug discovery opportunity Australia must seize
AI is expected to radically speed up drug discovery. But Australia risks falling behind.
Artificial intelligence is revolutionising the global pharmaceutical industry, yet Australia risks being left behind. While the nation is a world leader in clinical trials, it is significantly lagging in the adoption of AI in the early stages of drug discovery, a critical sector poised to slash healthcare costs and fast-track medical breakthroughs.
This quiet underperformance represents a strategic misstep and a major missed opportunity for Australia to capitalise on its unique strengths in research, talent and population diversity.
The traditional drug discovery process is notoriously slow and expensive, taking an average of 12 years and $2.6 billion to bring a single new drug to market. And artificial intelligence is set to radically change these figures. By accelerating every stage of the process, from identifying novel drug targets and designing new molecules to predicting clinical trial success, AI can cut preclinical development time and costs by 25% to 50%.
Despite this global shift, Australia's adoption of AI in drug discovery is progressing slowly. A key factor is the relative absence of large-scale pharmaceutical research and development headquarters. Major global pharmaceutical companies, the primary drivers of AI adoption, tend to concentrate their R&D efforts in established hubs in North America, Europe and Asia. This has created a paradox where Australia is a premier destination for clinical trials on humans, thanks to its streamlined regulatory framework and high-quality research infrastructure, but remains under-leveraged in the earlier, AI-intensive phases where the most significant value is generated.
